Ziprasidone (marketed as Geodon Zeldox by Pfizer) was the fifth atypical antipsychotic to gain approval (February 2001) in the United States. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia and acute mania and mixed states associated with bipolar disorder.
This page contains content from the copyrighted Wikipedia article "Ziprasidone"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
